Drugs / ANT3310
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06916156 | Apr → Aug 2025 | — | Antabio | Completed | No outcome recorded |
| Phase 1 | NCT06527677 | Jul 2024 → Jul 2025 | impaired renal function disease | Antabio | Completed | No outcome recorded |
| Phase 1 | NCT05905913 | Apr 2023 → Jan 2024 | — | Antabio | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-04-27 | Antabio | Results Antabio Highlights New Data on their Novel β‑lactam/β‑lactamase Inhibitor, Meropenem-Pilabactam (formerly Meropenem-ANT3310) at the 36th Congress of the European Society of Clinical Microbiology and Infectious Diseases antabio.com ↗
Data from Phase 1 studies showed favorable safety and PK profiles in renally-impaired subjects and good lung penetration in healthy volunteers. |
| 2024-09-03 | Antabio | Results Antabio Announces Successful Completion of Phase 1 Clinical Study of MEM-ANT3310 for Severe Hospital Infections antabio.com ↗
ANT3310 was well-tolerated at all doses with no serious adverse events, dose-limiting toxicities or clinically relevant abnormalities reported. |
| 2020-05-06 | Antabio | Regulatory Antabio Receives FDA Qualified Infectious Disease Product (QIDP) Designation for MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens antabio.com ↗
Antabio SAS announced today that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to Antabio’s MEM-ANT3310, a combination of meropenem (MEM) and the novel broad-spectrum serine beta-lactamase inhibitor ANT3310. |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANT3310 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06527677 ↗ |
| Action | Inhibit | “ANT3310, a novel, specific, competitive inhibitor of serine β-lactamases” NCT05905913 ↗ |
| Route | Intravenous | “ANT3310 will be infused over 3 hours” NCT05905913 ↗ |